‘Real life’ research model for improvement of personalised immunotherapy in cancer

Pinterest LinkedIn Tumblr +

Researchers from the Netherlands Cancer Institute and others have shown that it is possible to obtain immune cells (so-called killer T cells) from the bloodstream of a cancer patient and expand them in a dish together with a living piece of tumour from the same patient.

Such a tumour piece is called a tumour organoid.

The immune cells develop the ability to kill the tumour cells and to reduce organoid size, while leaving healthy control tissue of the same patient untouched.

This gives research into immunotherapy an instrument with which, for an individual patient — but outside the body — the complex interaction between immune cells and cancer cells can be studied.

The researchers will also use this new research platform to enable – in the long term – cellular immunotherapy: treatment of the patient with his  or her own immune cells as ‘living drugs.’

Researchers Krijn Dijkstra, Chiara Cattaneo et al. will publish these results on the website of the scientific journal Cell.

The research was led by Emile Voest and Ton Schumacher.

Recently, tumour organoids have been shown to retain the morphological and mutational properties of the original tumour.

This has opened the door to studying tumours outside the patient’s body and to testing the effects of various drugs.

However, tumour organoids had not yet been used to study immunotherapy.

Now, that has become possible.

Krijn Dijkstra, physician-researcher who is writing his doctoral thesis on this study, says “to answer our questions about whether or not immune therapy is successful, there is a great need for good “real life” models. This is certainly going to help.”

“We were anxiously waiting for such a research platform,” says Voest, who has led the research. “And there are no laboratory animals involved.”

This new tumour model allows researchers to more easily study the big questions and bottlenecks that now frustrate the wide clinical application of immunotherapy.

For example: why does one patient respond well to immunotherapy and another not at all?

How do cancer cells bypass the immune system and how do immune cells react to that?

And finally: how can we intervene in all these mechanisms?

The organoids were cultured from tumour tissue from 13 patients with a specific form of colorectal cancer (mismatch repair deficient colorectal cancer) and 6 patients with non-small cell lung cancer.

These subtypes of cancer are partly sensitive to immunotherapy, because the amount of DNA damage is so substantial that the immune system recognizes the cancer cells as ‘foreign’.

However, only a minority of patients with metastatic cancer responds well to immunotherapy.

Using organoids, immune cells from the blood of about one in three patients were successfully ‘trained’ to recognize tumour cells.

The immune cells in question are T cells. T cells (for the expert: type CD8 ) are white blood cells with a dual function: they recognize foreign elements and kill them as well, hence the nickname killer T cells.

From the bloodstream, they infiltrate and attack the tumour. In the forms of immunotherapy that are now used – as standard treatment or experimentally – these T cells take the front stage.

However, in the micro-environment of the tumour, all kinds of mechanisms are at work that make it impossible, or no longer possible, for T cells to recognize or kill the cancer cells.

These mechanisms can now be studied better.

Immunotherapy is aimed at strengthening and/or expanding T cells in the tumour microenvironment.

Immunotherapy was first applied to cutaneous melanoma, an aggressive form of skin cancer, and only afterwards to several other cancers.

“With melanoma, it is relatively easy to grow T cells from the tumour itself,” says Voest. “That has proved much more difficult with epithelial cancers such as colorectal cancer and lung cancer.”

That is why he is so happy that his group has succeeded in obtaining T cells from the bloodstream.

“T cells from the bloodstream are also likely to be ‘fresher’ than T cells that have already become exhausted during their stay in the tumour microenvironment.”

The new discovery also opens the way to develop cellular therapy in which T cells are ‘trained’ outside the body to recognize the tumour and then returned to the patient.

The organoids can likewise be used to test combinations of immunotherapy and other therapies.

SourceNetherlands Cancer Institute


About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.